-
Featured
CAR T-cell Therapy Shows Promise for Refractory/Relapsed Multiple Myeloma
Noopur Raje, MD, of the Massachusetts General Hospital Cancer Center, and colleagues determined in a phase 1 trial that idecabtagene vicleucel had promising antitumor activity in a heavily pretreated population of patients with multiple myeloma, and most nonhematologic toxic effects were grade 1 or 2.
-
Neutropenia-driven Approach to G-CSF Use May Be Feasible With CAR T-Cell Therapy
Mass General Cancer Center researchers found using granulocyte colony-stimulating factor to treat neutropenia after chimeric antigen receptor T-cell therapy, rather than as prophylaxis, resulted in less risk of severe cytokine release syndrome (CRS). Initiating G-CSF after CRS onset did not exacerbate toxicity.
-
Novel Tandem CAR T-Cell Effective Against Heterogeneous Glioblastoma
Massachusetts General Hospital researchers have developed TanCART, the first chimeric antigen receptor T cell that targets EGFRvIII and IL-13R?2 simultaneously, and found it was effective in vitro and in murine models of heterogeneous glioblastoma, including patient-derived xenografts.
-
Distinct Cellular Dynamics Are Associated With Response to CAR-T Therapy for B-Cell Lymphoma
Marcela V. Maus, MD, PhD, Gad Getz, PhD and colleagues observed that even small increases in CAR regulatory T cells contributed to relapse after axicabtagene ciloleucel treatment of refractory large B-cell lymphoma. This and other findings may optimize the design and individualization of CAR T-cell therapies.
-
Enhanced Interferon Signaling May Improve CAR T-cell Immunotherapy for Solid Tumors
Marcela V. Maus, MD, PhD, Rebecca C. Larson, PhD, and colleagues found that loss of genes in the interferon-gamma receptor signaling pathway is a mechanism of resistance to chimeric antigen receptor (CAR) T-cell therapy, suggesting a way to improve CAR T-cell treatment design for solid tumors.
-
Combination Strategy Potentiates CAR T-cell Therapy for Acute Myeloid Leukemia
Acute myeloid leukemia has been challenging to treat with CAR T-cell therapy. Still, Marcela V. Maus, MD, PhD, Mark B. Leick, MD, and colleagues demonstrated good preclinical results after developing a non-cleavable "hinge" for CD70-targeted T cells and pretreating with azacitidine.
CAR T-cell Therapy Contributors
-
Bob S. Carter, MD, PhD
Chief, Neurosurgery Service
Recent Article
Novel Tandem CAR T-Cell Effective Against Heterogeneous Glioblastoma
-
Daniel B. Rubin, MD, PhD
Neurologist
Recent Article
Interim Safety Profile From the Feasibility Study of the BrainGate Neural Interface System
-
Jeremy Slade Abramson, MD
Director, Jon and JoAnn Hagler Center for Lymphoma, Mass General Cancer Center, Associate Professor of Medicine, Harvard Medical School
Recent Article
Neutropenia-driven Approach to G-CSF Use May Be Feasible With CAR T-Cell Therapy
-
Meghan E. Sise, MD
Nephrologist, Massachusetts General Hospital, Associate Professor of Medicine
Recent Article
Acute Kidney Injury Possible with Tisagenlecleucel CAR T Therapy
-
Noopur S. Raje, MD
Director of the Multiple Myeloma Center, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School
Recent Article
CAR T-cell Therapy Shows Promise for Refractory/Relapsed Multiple Myeloma
-
Tomas G. Neilan, MD, MPH
Director, Cardio-Oncology Program, Massachusetts General Hospital, Co-Director, Cardiac MR PET CT Program
Recent Article
T1 Value on Cardiac MRI Diagnoses Myocarditis Associated with Checkpoint Inhibitors
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Novel Tandem CAR T-Cell Effective Against Heterogeneous Glioblastoma
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
